5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          ZBP1 is an interferon‐induced cytosolic nucleic acid sensor that facilitates antiviral responses via RIPK3. Although ZBP1‐mediated programmed cell death is widely described, whether and how it promotes inflammatory signaling is unclear. Here, we report a ZBP1‐induced inflammatory signaling pathway mediated by K63‐ and M1‐linked ubiquitin chains, which depends on RIPK1 and RIPK3 as scaffolds independently of cell death. In human HT29 cells, ZBP1 associated with RIPK1 and RIPK3 as well as ubiquitin ligases cIAP1 and LUBAC. ZBP1‐induced K63‐ and M1‐linked ubiquitination of RIPK1 and ZBP1 to promote TAK1‐ and IKK‐mediated inflammatory signaling and cytokine production. Inhibition of caspase activity suppressed ZBP1‐induced cell death but enhanced cytokine production in a RIPK1‐ and RIPK3 kinase activity‐dependent manner. Lastly, we provide evidence that ZBP1 signaling contributes to SARS‐CoV‐2‐induced cytokine production. Taken together, we describe a ZBP1‐RIPK3‐RIPK1‐mediated inflammatory signaling pathway relayed by the scaffolding role of RIPKs and regulated by caspases, which may induce inflammation when ZBP1 is activated below the threshold needed to trigger a cell death response.

          Abstract

          ZBP1 is a nucleic acid sensor that induces cell death via RIPK3. This study describes a ZBP1‐induced inflammatory signaling pathway that is independent of cell death and is mediated by non‐degradative ubiquitin chains, and RIPK1 and RIPK3 as scaffolds.

          Related collections

          Most cited references79

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

            Summary Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response. This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6. We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Analyzing real-time PCR data by the comparative C(T) method.

              Two different methods of presenting quantitative gene expression exist: absolute and relative quantification. Absolute quantification calculates the copy number of the gene usually by relating the PCR signal to a standard curve. Relative gene expression presents the data of the gene of interest relative to some calibrator or internal control gene. A widely used method to present relative gene expression is the comparative C(T) method also referred to as the 2 (-DeltaDeltaC(T)) method. This protocol provides an overview of the comparative C(T) method for quantitative gene expression studies. Also presented here are various examples to present quantitative gene expression data using this method.
                Bookmark

                Author and article information

                Contributors
                mgyrd@sund.ku.dk
                Journal
                EMBO Rep
                EMBO Rep
                10.1002/(ISSN)1469-3178
                EMBR
                embor
                EMBO Reports
                John Wiley and Sons Inc. (Hoboken )
                1469-221X
                1469-3178
                21 October 2022
                December 2022
                21 October 2022
                : 23
                : 12 ( doiID: 10.1002/embr.v23.12 )
                : e55839
                Affiliations
                [ 1 ] Nuffield Department of Medicine, Ludwig Institute for Cancer Research University of Oxford Oxford UK
                [ 2 ] Department of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center University of Copenhagen Copenhagen Denmark
                [ 3 ] Department of Biomedicine Aarhus University Aarhus C Denmark
                [ 4 ] Department of Immunology University of Washington Seattle WA USA
                [ 5 ] Division of Immunology Federal Institute for Vaccines and Biomedicines, Paul‐Ehrlich‐Institut Langen Germany
                [ 6 ] MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine University of Oxford Oxford UK
                [ 7 ] VIB‐UGent Center for Inflammation Research Ghent Belgium
                [ 8 ] Department of Biomedical Molecular Biology Ghent University Ghent Belgium
                Author notes
                [*] [* ]Corresponding author. Tel: +45 2434 0323; E‐mail: mgyrd@ 123456sund.ku.dk
                Author information
                https://orcid.org/0000-0001-5488-4399
                https://orcid.org/0000-0002-3511-2550
                https://orcid.org/0000-0003-4463-1165
                https://orcid.org/0000-0003-1741-6275
                https://orcid.org/0000-0002-6587-1152
                https://orcid.org/0000-0003-0269-6454
                https://orcid.org/0000-0003-3841-835X
                https://orcid.org/0000-0002-1476-0583
                https://orcid.org/0000-0001-9180-4060
                https://orcid.org/0000-0001-5641-5019
                Article
                EMBR202255839
                10.15252/embr.202255839
                9724671
                36268590
                cf079497-5eff-46aa-ab0e-66f415a226ef
                © 2022 The Authors. Published under the terms of the CC BY 4.0 license.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 06 October 2022
                : 22 July 2022
                : 07 October 2022
                Page count
                Figures: 13, Tables: 0, Pages: 32, Words: 23987
                Funding
                Funded by: China Scholarship Council‐University of Oxford DPhil Scholarship
                Award ID: GAF1516_CSCUO_841725
                Funded by: EC¦European Research Council (ERC) , doi 10.13039/501100000781;
                Award ID: ERC‐AdG ENVISION; 786602
                Funded by: LEO Fondet (LEO Foundation) , doi 10.13039/501100012331;
                Funded by: Ludwig Institute for Cancer Research (LICR) , doi 10.13039/100009729;
                Funded by: Novo Nordisk Fonden (NNF) , doi 10.13039/501100009708;
                Award ID: NNF20OC0059392
                Award ID: NNF18OC0030274
                Funded by: The independent research fund Denmark
                Award ID: 0214‐00001B
                Funded by: Wellcome Trust (WT) , doi 10.13039/100010269;
                Award ID: 102894/Z/13/Z
                Award ID: 215612/Z/19/Z
                Categories
                Article
                Articles
                Custom metadata
                2.0
                06 December 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.2 mode:remove_FC converted:06.12.2022

                Molecular biology
                inflammatory signaling,ripk1,ripk3,sars‐cov‐2,zbp1,immunology,post-translational modifications & proteolysis,signal transduction

                Comments

                Comment on this article